Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02714205 · ClinicalTrials.gov registry record · Phase 2
Flushing Reduction Associated With Nitrates
A Phase 2 study of Menopausal Hot Flashes, sponsored by Alison Huang, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
- 2
- Study locations
NCT02714205: Completed Phase 2 study of Menopausal Hot Flashes, sponsored by Alison Huang, MD.
NCT02714205 is a Phase 2 study of Menopausal Hot Flashes that has completed, run by Alison Huang, MD. The registered enrollment target is 141 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02714205, a Phase 2 study of Menopausal Hot Flashes, has completed, sponsored by Alison Huang, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
- 2
- Study locations
Study Summary
A randomized, double-blinded, placebo-controlled trial of uninterrupted transdermal nitrate therapy in 140 peri- or postmenopausal women who have frequent hot flashes. Women will be randomly assigned to uninterrupted use of transdermal nitrate therapy (participant directed dose-escalation of 0.2 to 0.6 mg/hr) or identical-appearing placebo patches for 12 weeks.
Primary Outcome
Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG transdermal nitroglycerin
Study Locations (2)
California
- University of California, San Francisco - Oakland
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2022-04-05 |
| Phase | Phase 2 |
What the finished NCT02714205 record still lists
NCT02714205 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Menopausal Hot Flashes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02714205 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02714205 about?
NCT02714205 is a clinical study titled "Flushing Reduction Associated With Nitrates". A randomized, double-blinded, placebo-controlled trial of uninterrupted transdermal nitrate therapy in 140 peri- or postmenopausal women who have frequent hot flashes. Women will be randomly assigned to uninterrupted use of transdermal nitrate therapy (participant directed dose-escalation of 0.2 to ...
What is the current status of trial NCT02714205?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2017-04-24. Estimated completion is 2022-04-05.
What conditions does trial NCT02714205 study?
This clinical trial studies the following conditions: Menopausal Hot Flashes.
What interventions are being tested in trial NCT02714205?
The interventions under investigation include: Placebo (DRUG), transdermal nitroglycerin (DRUG).
Who is sponsoring clinical trial NCT02714205?
This trial is sponsored by Alison Huang, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02714205 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02714205's enrollment target sits among peer trials
141 510th of 2000 higher than 1,489 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI